Welcome to STN International!   Enter x:x

LOGINID:sssptal600rxa

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * *   Welcome to STN International   * * * * * * * * *

```
NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
NEWS  2   Apr 08  "Ask CAS" for self-help around the clock
NEWS  3   Apr 09  BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS  4   Apr 09  ZDB will be removed from STN
NEWS  5   Apr 19  US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS  6   Apr 22  Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS  7   Apr 22  BIOSIS Gene Names now available in TOXCENTER
NEWS  8   Apr 22  Federal Research in Progress (FEDRIP) now available
NEWS  9   Jun 03  New e-mail delivery for search results now available
NEWS 10   Jun 10  MEDLINE Reload
NEWS 11   Jun 10  PCTFULL has been reloaded
NEWS 12   Jul 02  FOREGE no longer contains STANDARDS file segment
NEWS 13   Jul 22  USAN to be reloaded July 28, 2002;
                  saved answer sets no longer valid
NEWS 14   Jul 29  Enhanced polymer searching in REGISTRY
NEWS 15   Jul 30  NETFIRST to be removed from STN
NEWS 16   Aug 08  CANCERLIT reload
NEWS 17   Aug 08  PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18   Aug 08  NTIS has been reloaded and enhanced
NEWS 19   Aug 19  Aquatic Toxicity Information Retrieval (AQUIRE)
                  now available on STN
NEWS 20   Aug 19  IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21   Aug 19  The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22   Aug 26  Sequence searching in REGISTRY enhanced
NEWS 23   Sep 03  JAPIO has been reloaded and enhanced
NEWS 24   Sep 16  Experimental properties added to the REGISTRY file
NEWS 25   Sep 16  CA Section Thesaurus available in CAPLUS and CA
NEWS 26   Oct 01  CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27   Oct 21  EVENTLINE has been reloaded
NEWS 28   Oct 24  BEILSTEIN adds new search fields
NEWS 29   Oct 24  Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30   Oct 25  MEDLINE SDI run of October 8, 2002
NEWS 31   Nov 18  DKILIT has been renamed APOLLIT
NEWS 32   Nov 25  More calculated properties added to REGISTRY
NEWS 33   Dec 02  TIBKAT will be removed from STN
NEWS 34   Dec 04  CSA files on STN
NEWS 35   Dec 17  PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36   Dec 17  TOXCENTER enhanced with additional content
NEWS 37   Dec 17  Adis Clinical Trials Insight now available on STN
NEWS 38   Dec 30  ISMEC no longer available
NEWS 39   Jan 13  Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40   Jan 21  NUTRACEUT offering one free connect hour in February 2003
NEWS 41   Jan 21  PHARMAML offering one free connect hour in February 2003
NEWS 42   Jan 29  Simultaneous left and right truncation added to COMPENDEX,
                  ENERGY, INSPEC
NEWS 43   Feb 13  CANCERLIT is no longer being updated
NEWS 44   Feb 24  METADEX enhancements
NEWS 45   Feb 24  PCTGEN now available on STN
```

```
NEWS 46   Feb 24   TEMA now available on STN
NEWS 47   Feb 26   NTIS now allows simultaneous left and right truncation
NEWS 48   Feb 26   PCTFULL now contains images

NEWS EXPRESS   January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS     STN Operating Hours Plus Help Desk Availability
NEWS INTER     General Internet Information
NEWS LOGIN     Welcome Banner and News Items
NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
NEWS WWW       CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement. Please note that this agreement limits use to scientific
  research. Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

    * * * * * * * * * * * * STN   Columbus   * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:28:39 ON 03 MAR 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 07:28:47 ON 03 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 FEB 2003   HIGHEST RN 496269-39-7
DICTIONARY FILE UPDATES: 28 FEB 2003   HIGHEST RN 496269-39-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10007235b.str

L1   STRUCTURE UPLOADED

```
=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 07:29:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1538 TO ITERATE

 65.0% PROCESSED    1000 ITERATIONS                      0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        28408 TO     33112
PROJECTED ANSWERS:               0 TO         0

L2          0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:29:14 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  29427 TO ITERATE

100.0% PROCESSED   29427 ITERATIONS                      7 ANSWERS
SEARCH TIME: 00.00.02

L3         7 SEA SSS FUL L1

=> d scan
```

L3   7 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS
IN   Formamide, N-[3-[4-[[2-amino-1-oxo-3-(4-thiazolyl)propyl]amino]-5-
      cyclohexyl-2,4,5-trideoxy-L-threo-pentonoyl]phenyl]-N-methyl-, (S)- (9CI)
MF   C25 H34 N4 O4 S

Absolute stereochemistry.


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L3   7 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS
IN   Formamide, N-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[4-
      morpholinylsulfonyl]-L-phenylalanyl]-5-(4-thiazolyl)-L-alenyl]amino]-L-
      threo-pentonoyl]phenyl]-N-methyl- (9CI)
MF   C38 H50 N6 O8 S2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3   7 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS
IN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[(1,1-
      dimethylethoxy)carbonyl]amino]-3-[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-
      4-yl]-1-oxopropyl]amino]-L-threo-pentonoyl]benzoyl]-, (S)- (9CI)
MF   C40 H53 N5 O9 S

Absolute stereochemistry.

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

L3   7 ANSWERS   REGISTRY   COPYRIGHT 2003 ACS
IN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[(1,1-
      dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-3-(1H-imidazol-
      4-yl)-1-oxopropyl]amino]-L-threo-pentonoyl]benzoyl]-, [S-(R*,R*)]- (9CI)
MF   C42 H57 N5 O8 S

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3   7 ANSWERS   REGISTRY COPYRIGHT 2003 ACS
IN   Foreamide, N-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[(1,1-
      dimethylethoxy)carbonyl]amino]-1-oxo-3-(4-thiazolyl)propyl]amino]-L-threo-
      pentonoyl]phenyl]-N-methyl-, (S)- (9CI)
MF   C30 H42 N4 O6 S

Absolute stereochemistry.

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3   7 ANSWERS   REGISTRY COPYRIGHT 2003 ACS
IN   Morpholine, 4-[3-[4-[[2-amino-3-[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-
      4-yl]-1-oxopropyl]amino]-5-cyclohexyl-2,4,5-trideoxy-L-threo-
      pentonoyl]benzoyl]-, (S)- (9CI)
MF   C35 H45 N5 O7 S

Absolute stereochemistry.


PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3   7 ANSWERS   REGISTRY COPYRIGHT 2003 ACS
IN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[2-[[(1,1-
      dimethylethyl)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-3-[1-[(4-
      methylphenyl)sulfonyl]-1H-imidazol-4-yl]-1-oxopropyl]amino]-L-threo-
      pentonoyl]benzoyl]-, (S-(R*,R*)]- (9CI)
MF   C49 H63 N5 O10 S2

PAGE 1-A

PAGE 2-A

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> fil caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   148.15     148.36

FILE 'CAPLUS' ENTERED AT 07:29:38 ON 03 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Mar 2003  VOL 138 ISS 10
FILE LAST UPDATED: 2 Mar 2003  (20030302/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l3
L4            1 L3

=> d ibib abs hitstr
```

L4   ANSWER 1 OF 1 CAPLUS   COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1992:449265 CAPLUS
DOCUMENT NUMBER: 117:49265
TITLE: Preparation of dipeptide renin inhibitors
INVENTOR(S):   Toyoda, Tatsuo; Fujioka, Toshihiro; Hayashi, Kunio;
                     Nakamura, Masahisa; Hashimoto, Naofumi
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 117 pp.
                     CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

     PATENT NO.   KIND DATE   APPLICATION NO.   DATE
     -----------   ---- ----------- ---------------   -----------
     EP 468641   A2   19920129   EP 1991-305763   19910626
     EP 468641   A3   19930113
     R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE
     CA 2045008   A   19911229   CA 1991-2045008   19910619
     US 5194608   A   19930316   US 1991-719492   19910624
     AU 3179304   A1   19920102   AU 1991-79304   19910626
     AU 643036   B2   19931104
     HU 58346   A2   19920228   HU 1991-2166   19910627
     JP 05009162   A2   19930119   JP 1991-156764   19910627
     JP 2997695   B2   20000111
     US 5223615   A   19930629   US 1992-974212   19921110
     US 5272268   A   19931221   US 1992-974211   19921110
     AU 9144490   A1   19931125   AU 1993-44490   19930826
     AU 653682   B2   19941006

PRIORITY APPLN. INFO.:   JP 1990-172050   A 19900628
                                       US 1991-719492   A3 19910624
OTHER SOURCE(S):   MARPAT 117:49265
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB   Title compds. [I; R1 = (substituted) (cyclo)alkyl, alkenyl, alkynyl,
     heterocyclyl; R2 = (substituted) carbamoyl, aryl, heterocyclyl, alkyl,
     alkylthioalkyl, alkylthio; R3 = (substituted) aryl, 5- to 6-membered
     heterocyclyl; R4 = R5SO2, R5CO; R5 = (substituted) aryl, (cyclo)alkyl,
     alkenyl, alkynyl, heterocyclyl; X = CH2, NH, O, S; Y = CO, NHSO2], were
     prepd. Thus, N-(tert-butoxycarbonyl)cyclohexylalaninal was condensed with
     4-acetylpyridine using NaN(SiMe3)2 and 15-crown-5 in THF to give a mixt.
     of aldol condensation epimers, which was treated with H2CrI(Me)OEt and
     p-MeOC6H4CHO to give oxaziolidine II (BOC = MeICO2C). This was
     successively reduced with NaBH4, deketalized with HCl or CF3CO2H, coupled
     with BOC-His(Tos)-OH (Tos = tosyl), and oxidized with MnO2 to give
     intermediate III. III was N-deprotected with CF3CO2H, acylated with
     3-tert-butylsulfonyl-2S-phenylpropionic acid, and N'-deprotected with
     pyridinium hydrochloride to give the compd. I. I at 15 mg/kg orally in
     monkeys pretreated with furosemide gave 33-99% inhibition of renin.
     Several I at 1-100 mg/kg orally or i.v. effectively reduced blood pressure
     in monkeys.

L4   ANSWER 1 OF 1 CAPLUS   COPYRIGHT 2003 ACS   (Continued)

PAGE 1-A

PAGE 2-A

RN   141578-42-9 CAPLUS
CN   Formamide, N-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[4-
     morpholinylsulfonyl]-L-phenylalanyl]-3-(4-thiazolyl)-L-alanyl]amino]-L-
     threo-pentonoyl]phenyl]-N-methyl- (9CI)   (CA INDEX NAME)

L4   ANSWER 1 OF 1 CAPLUS   COPYRIGHT 2003 ACS   (Continued)
IT   141597-33-3P 141597-38-8P
     RL: SPN (Synthetic preparation); PREP (Preparation)
         (prepn. of, as intermediate for peptide renin inhibitor)
RN   141597-33-3 CAPLUS
CN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[[(1,1-
     dimethylethoxy)carbonyl]amino]-3-[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-
     4-yl]-1-oxopropyl]amino]-L-threo-pentonoyl]benzoyl]-, (S)- (9CI) (CA
     INDEX NAME)

Absolute stereochemistry.

RN   141597-38-8 CAPLUS
CN   Formamide, N-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[(1,1-
     dimethylethoxy)carbonyl]amino]-1-oxo-3-[4-thiazolyl]propyl]amino]-L-threo-
     pentonoyl]phenyl]-N-methyl-, (S)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

IT   141578-33-9P 141578-42-9P 141578-63-4P
     141578-90-7P 141578-99-6P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
         study, unclassified); SPN (Synthetic preparation); BIOL (Biological
         study); PREP (Preparation)
         (prepn. of, as renin inhibitor)
RN   141578-33-9 CAPLUS
CN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[(1,1-

L4   ANSWER 1 OF 1 CAPLUS   COPYRIGHT 2003 ACS   (Continued)

RN   141578-63-4 CAPLUS
CN   Morpholine, 4-[3-[5-cyclohexyl-2,4,5-trideoxy-4-[[2-[[[(1,1-
     dimethylethoxy)sulfonyl]methyl]-1-oxo-3-phenylpropyl]amino]-3-(1H-imidazol-
     4-yl]-1-oxopropyl]amino]-L-threo-pentonoyl]benzoyl]-, [S-(R*,R*)]- (9CI)
     (CA INDEX NAME)

RN   141578-90-7 CAPLUS
CN   Morpholine, 4-[3-[4-[[2-amino-3-[1-[(4-methylphenyl)sulfonyl]-1H-imidazol-
     4-yl]-1-oxopropyl]amino]-5-cyclohexyl-2,4,5-trideoxy-L-threo-
     pentonoyl]benzoyl]-, (S)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

RN   141576-99-6 CAPLUS
CN   Formamide, N-[3-[4-[[2-amino-1-oxo-3-(4-thiazolyl)propyl]amino]-5-
     cyclohexyl-2,4,5-trideoxy-L-threo-pentonoyl]phenyl]-N-methyl-, (S)- (9CI)
     (CA INDEX NAME)

Absolute stereochemistry.

```
=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY     SESSION
FULL ESTIMATED COST                                      5.79      154.15

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                        ENTRY     SESSION
CA SUBSCRIBER PRICE                                     -0.65       -0.65

FILE 'REGISTRY' ENTERED AT 07:31:26 ON 03 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 FEB 2003  HIGHEST RN 496269-39-7
DICTIONARY FILE UPDATES:  28 FEB 2003  HIGHEST RN 496269-39-7

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10007235b.str

L5      STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l5
SAMPLE SEARCH INITIATED 07:31:50 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  18750 TO ITERATE

  5.3% PROCESSED    1000 ITERATIONS                             0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:      366817 TO   383183
```

```
PROJECTED ANSWERS:                    0 TO        0

L6            0 SEA SSS SAM L5

=> s 15 full
FULL SEARCH INITIATED 07:31:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 369190 TO ITERATE

 99.3% PROCESSED  366467 ITERATIONS                              107 ANSWERS

100.0% PROCESSED  369190 ITERATIONS                             107 ANSWERS
SEARCH TIME: 00.00.20

L7          107 SEA SSS FUL L5

=> fil calplus
'CALPLUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> fil caplus
COST IN U.S. DOLLARS                      SINCE FILE      TOTAL
                                             ENTRY       SESSION
FULL ESTIMATED COST                         148.55       302.70


DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                             ENTRY       SESSION
CA SUBSCRIBER PRICE                           0.00        -0.65

FILE 'CAPLUS' ENTERED AT 07:32:28 ON 03 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE COVERS 1907 - 3 Mar 2003  VOL 138 ISS 10
FILE LAST UPDATED: 2 Mar 2003  (20030302/ED)

   This file contains CAS Registry Numbers for easy and accurate
   substance identification.


=> s 17
L8          40 L7
```

```
=> s l8 and aspartyl protease
          4501 ASPARTYL
             5 ASPARTYLS
          4504 ASPARTYL
                (ASPARTYL OR ASPARTYLS)
         73802 PROTEASE
         26974 PROTEASES
         85915 PROTEASE
                (PROTEASE OR PROTEASES)
           511 ASPARTYL PROTEASE
                (ASPARTYL(W)PROTEASE)
L9           2 L8 AND ASPARTYL PROTEASE

=> d ibib abs hitstr 1-2
```

L9   ANSWER 1 OF 2 CAPLUS   COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:708752 CAPLUS
DOCUMENT NUMBER: 131:322921
TITLE: Preparation of hydroxypropylamide peptidomimetics as
                        inhibitors of aspartyl proteases
INVENTOR(S):   Dolle, Roland Ellwood, III; Cavallaro, Cullen Lee;
                        Herpin, Timothee Felix
PATENT ASSIGNEE(S):   Pharmacopeia, Inc., USA
SOURCE: PCT Int. Appl., 48 pp.
                        CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955687	A2	19991104	WO 1999-US9070	19990427
WO 9955687	A3	20000224		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
    DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
    JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
    MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
    TM, TR, TT, UA, UG, UZ, VN, VU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
    RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
    ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
    CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 5986102   A   19991116   US 1998-69300   19990429
AU 9636644   A1   19991116   AU 1999-38604   19990427
US 6191277   B1   20010220   US 1998-69300   A   19980429
PRIORITY APPLN. INFO.:   US 1998-69300   A   19980429
                                       WO 1999-US9070 W   19990427
OTHER SOURCE(S):   MARPAT 131:322921
GI

                            1

AB Compds. Z-NR2CH(R1CH(OH)CH2CH2-Y [R1 = alkyl, -(CH2)n-cycloalkyl (n = 1-3),
    aralkyl; R2 = H or [S]-CD-L-, where [S] is a solid support and -L- is a
    linker; Y = OZCNR3 or NR4R5, where R3 is alkyl, aralkyl, aryl, or
    acyloxyalkyl and R4 and R5 are independently H, alkoxyalkyl, R3, CCN3,
    SO2R3, Z-indanyl(CH2)n (n = 2-3) or R4R5N is morpholino or N-substituted
    1-piperazinyl; Z = CO?7, COCNR4O2CNNR3, COCN8RNNCCO3, where R7 is alkyl,
    aralkyl, aryl, -(CH2)n-cycloalkyl, heteroary], 1-(carboxy

L9   ANSWER 1 OF 2 CAPLUS   COPYRIGHT 2003 ACS   (Continued)

RN 248596-62-5 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-1,2,4,5-tetradeoxy-1-(3,4-
    dichlorophenyl)-2-[(1-oxo-3,3-diphenylpropyl)amino]-, (3.xi.)- (9CI) (CA
    INDEX NAME)

Absolute stereochemistry.

RN 248596-63-6 CAPLUS
CN Benzamide, N-[[1S]-1-[3-(4-acetyl-1-piperazinyl)-1-hydroxypropyl]pentyl]-2-
    fluoro-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 248596-64-7 CAPLUS
CN Butanamide, N-[[1S]-4-(4-acetyl-1-piperazinyl)-2-hydroxy-1-(2-
    phenylethyl)butyl]-3-methyl-2-[[(phenylamino)carbonyl]oxy]-, (2S)- (9CI)
    (CA INDEX NAME)

Absolute stereochemistry.

L9   ANSWER 1 OF 2 CAPLUS   COPYRIGHT 2003 ACS   (Continued)
ester)-2-pyrrolidinyl, 2-indanyl-(CH2)n and R8 = H, alkyl, aralkyl,
-(CH2)n-cycloalkyl] were prepd. as inhibitors having activity against the
aspartyl proteases plasmepsin and cathepsin D. Thus,
compd. 1 was prepd. by the solid-phase method and shown to inhibit
plasmepsin or cathepsin D at a concn. (IC50) of less than 350 micromolar.
IT 248596-60-3P 248596-61-4P 248596-62-5P
    248596-63-6P 248596-64-7P 248596-65-8P
    248596-66-9P 248596-67-0P 248596-68-1P
    248596-69-2P
RL RAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
    BIOL (Biological study); PREP (Preparation); USES (Uses)
    (prepn. of hydroxypropylamide peptidomimetics as inhibitors of
    aspartyl proteases)
RN 248596-60-3 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-1,2,4,5-tetradeoxy-1-(3,4-
    dichlorophenyl)-2-[(2,4-dimethoxybenzoyl)amino]-, (3.xi.)- (9CI) (CA
    INDEX NAME)

Absolute stereochemistry.

RN 248596-61-4 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-1,2,4,5-tetradeoxy-1-(3,4-
    dichlorophenyl)-2-[[2-fluoro-4-(trifluoromethyl)benzoyl]amino]-, (3.xi.)-
    (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9   ANSWER 1 OF 2 CAPLUS   COPYRIGHT 2003 ACS   (Continued)

RN 248596-65-8 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-2-[([1,1'-biphenyl]-4-
    ylcarbonyl)amino]-1-(4-chlorophenyl)-1,2,4,5-tetradeoxy-, (3.xi.)- (9CI)
    (CA INDEX NAME)

Absolute stereochemistry.

RN 248596-66-9 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-1-[1,1'-biphenyl]-4-yl-
    1,2,4,5-tetradeoxy-2-[[(2S)-3-methyl-2-[[[4-
    phenoxyphenyl)amino]carbonyl]oxy]butyl]amino]-, (3.xi.)- (9CI) (CA INDEX
    NAME)

Absolute stereochemistry.

RN 248596-67-0 CAPLUS
CN D-glycero-Pentitol, 5-(4-acetyl-1-piperazinyl)-2-
    [(cyclopropylcarbonyl)amino]-1,2,4,5-tetradeoxy-1-(3,4-dichlorophenyl)-,

L9   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS   (Continued)
(3.xi.)- (9CI)   (CA INDEX NAME)

Absolute stereochemistry.

RN   248596-68-1 CAPLUS
CN   D-glycero-Pentitol, 5-[4-acetyl-1-piperazinyl]-1,2,4,5-tetradeoxy-2-[[3-[4-
     (2-methoxyethoxy)phenyl]-1-oxopropyl]amino]-1-(4-methoxyphenyl)-, (3.xi.)-
     (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN   248596-69-2 CAPLUS
CN   Benzamide, N-[(1S)-4-(4-acetyl-1-piperazinyl)-2-hydroxy-1-(2-
     methylpropyl)butyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L9   ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS   (Continued)

L9   ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:613618 CAPLUS
DOCUMENT NUMBER: 125:157755
TITLE: A Novel Bicyclic Enzyme Inhibitor as a Consensus
                      Peptido-Mimetic for the Receptor-Bound Conformations
                      of Twelve Peptidic Inhibitors of HIV-1 Protease
AUTHOR(S):   Reid, Robert C.; March, Darren R.; Dooley, Michael J.;
                      Bergman, Doug A.; Abbenante, Giovanni; Fairlie, David
                      P.
CORPORATE SOURCE: Centre for Drug Design and Development, University of
                      Queensland, Brisbane, 4072, Australia
SOURCE: Journal of the American Chemical Society (1996),
                      118(36), 8511-8517
                      CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB   The X-ray crystal structures of 12 substrate-based peptidic inhibitors
     bound in the active site of the aspartyl protease,
     HIV-1 protease, have been compared. The inhibitor-binding modes of these
     inhibitors are remarkably similar despite their structural diversity and
     conformational flexibility. This prompted the design of a bicyclic
     peptidomimetic inhibitor with macrocyclic components in constrained
     conformations that are preorganized for receptor-binding. This inhibitor
     is a consensus conformational mimic of the protease-bound inhibitor
     structures with superior properties to peptides, including stability to
     acid and peptidases as well as antiviral activity. Each of the 15- and
     16-membered rings, formed through side-chain to backbone condensation,
     contains two proteolytically resistant amide bonds and either isoleucine
     or valine linked via a short aliph. spacer to tyrosine. The two cycles
     are connected by a hydroxyethylamine transition state isostere. Mol.
     modeling and NMR studies indicate that each macrocycle is a highly
     constrained structural mimic of tripeptide components of linear peptide
     substrates/inhibitors of HIV-1 protease. Thus the bicyclic peptidomimetic
     superimposes upon and structurally mimics acyclic hexapeptide inhibitors
     and their analogs. This results in functional mimicry, as demonstrated by
     comparable inhibition of HIV-1 proteases by acyclic and cyclic mols. at
     nanomolar concns. The rational design of cycles which fix receptor-bound
     conformations of bioactive peptides has potential applications in the
     structural mimicry of other bioactive peptides and may facilitate rational
     drug design.
IT   150348-92-8, SB 206343
     AL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
     (bicyclic enzyme inhibitor as consensus peptido-mimetic for
     receptor-bound conformations of peptidic inhibitors of HIV-1 protease)
RN   150348-92-8 CAPLUS
CN   Carbamic acid, [(1S)-1-[[[(1S,2S,4S)-2-hydroxy-4-(4-(2-methyl-1-oxopropyl)-
     1H-imidazol-2-yl]-5-phenyl-1-[phenylmethyl]pentyl]amino]carbonyl]-2-
     methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

```
=> log y
```

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	13.77	316.47

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.95

STN INTERNATIONAL LOGOFF AT 07:34:18 ON 03 MAR 2003

```
chain nodes :
    1   2   3   4   5   6   7   8   9   10  11  12  13  18  20  21  22  23  24  25  26
    27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44
    45  46  47  48  49  50  51  52  53  65  66
chain bonds :
    1-2  1-66  2-3  3-4  3-6  4-5  4-7  5-65  7-8  9-10  11-12  12-13  18-66
    20-21  22-29  23-28  23-30  24-31  24-32  25-26  25-36  26-27  27-37
    33-34  34-35  38-39  39-40  40-41  42-43  43-44  44-45  46-47  47-48
    48-49  50-51  51-52  52-53
exact/norm bonds :
    1-2  1-66  3-6  4-5  5-65  7-8  9-10  11-12  12-13  18-66  20-21  22-29
    23-28  23-30  24-31  24-32  25-26  25-36  26-27  27-37  33-34  34-35
    40-41  42-43  44-45  46-47  48-49  50-51  51-52  52-53
exact bonds :
    2-3  3-4  4-7  38-39  39-40  43-44  47-48  51-52
```

G1:Cb,Ak

G2:[*1],[*2]

G3:N,Ak

G4:[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10],[*11],[*12]

Match level :
    1:CLASS   2:CLASS   3:CLASS   4:CLASS   5:CLASS   6:CLASS   7:CLASS   8:CLASS
    9:CLASS

```
            10:CLASS   11:CLAS●12:CLASS   13:CLASS   18:C●S   20:CLASS
21:CLASS   22:CLASS   23:CLASS   24:CLASS   25:CLASS   26:CLASS   27:CLASS
28:CLASS   29:CLASS   30:CLASS   31:CLASS   32:CLASS   33:CLASS   34:CLASS
35:CLASS   36:CLASS   37:CLASS   38:CLASS   39:CLASS   40:CLASS   41:CLASS
42:CLASS   43:CLASS   44:CLASS   45:CLASS   46:CLASS   47:CLASS   48:CLASS
49:CLASS   50:CLASS   51:CLASS   52:CLASS   53:CLASS   65:CLASS   66:Atom
```